<h4>Background</h4>Up to 80% of breast cancers (BCa) are estrogen receptor positive and current treatments target the estrogen receptor (endocrine therapies) and/or CDK4/6 (CDK4/6 inhibitors). This evidence concerns the gene CDK4 and breast cancer.